1. The approach used in Transdermal drug delivery system is
- a. Sonophoresis
- b. Electrophoresis
- c. Both a and b
- d. None of the above
Ans: c
2. __ is the most noticeable disadvantages of gastroretentive floating drug delivery systems.
- a. Requirement of high level of fluid
- b. Delay release
- c. Absorption of acid soluble drug
- d. Vigorous intestinal movement
Ans: a
3. First transdermal patch approved in 1979 was for the following drug
- a. pain(fentanyl)
- b. Motion sickness(scopolamine)
- c. smoking cessation(nicotine)
- d. pain (lidocaine)
Ans: b
4. Physicochemical factor effecting TDDS
- a. Sun light
- b. Partition coefficient
- c. Air pollution
- d. Cold season
Ans: b
5. Drug eluting stents are the best example of TDDSs for
- a. Vascular disease treatment
- b. Pain management
- c. Diabetes
- d. All of the above
Ans: a
6. The rate at which monolithic devices transfer drugs to the patient body is proportional to ____of time.
- a. Square of time
- b. The square root of time
- c. Twice the time
- d. Half the time
Ans: b
7. The characteristic that is suitable for transdermal drug is
- a. Large drug dose
- b. large molecular size
- c. Drugs with narrow therapeutic index
- d. Drugs which are metabolized in the skin
Ans: c
8. The approaches that can be included in formulation of nasopulmonary drug delivery systems is/are
- a. liposome
- b. Microspheres
- c. nasal powder
- d. all of the above
Ans: d
9. The primary barrier to Transdermal drug delivery is-
- a. Dermis
- b. Epidermis(stratum corneum)
- c. Hypodermis
- d. all of the above
Ans: b
10. Preservative used in the Nasal spray is
- a) Paraben
- b) PEG
- c) Glycerine
- d)Acetone
Ans: a
11. Intranasal administration is an attractive route for _______action
- a. local
- b. Systemic
- c. none
- d. both
Ans: d
12. Not applicable for evaluation of TDDS
- a) Quick stick test
- b) probe tack test
- c) skim peel test
- d) thumb tack test
Ans:c
13. Test apparatus used to study drug release form TDDS
- a) Paddle over disc
- b) Rotating cylinder
- c) Basket apparatus
- d) Both a &b
Ans: d
14. Silicone, Polybutyl acrylate, polyisobutylene are examples of
- a) Backing membrane
- b) Polymer matrix
- c) Permeation enhancers
- d) Adhesives
Ans: d
15. Well developed “intercellular lipid lamellae” is a feature of which layer of the epithelium.
- a) Stratum basale
- b) Stratum spinosum
- c) Stratum lucidum
- d) Stratum corneum
Ans: d
16. Disadvantage of TDDS is
- a) Self-administration
- b) molecular size >500
- c) low drug level in blood/plasma
- d) none of them.
Ans: c
17. The mechanism of chemical permeation enhancer is
- a)Cause deposition of penetrant in the stratum corneum
- b)Alter physicochemical properties of stratum corneum
- c)Causes reversible damage to the stratum corneum
- d)Both b & c
Ans: d
18. Iontophoresis is used in TDDS as
- a) Physical penetration enhancer
- b)Chemical penetration enhancer
- c)Drug carrier
- d)Polymer matrix
Ans: a
19. ————— cannot be given as transdermal administration
- a) Drugs with very short half-lives
- b) Drugs with narrow therapeutic indices
- c) Easy removal and termination
- d) Drugs against peptic ulcer
Ans: d
20. Components of trandermal drug delivery system is/ are
- a. Drug substance
- b. Polymer matrix
- c. Backing membrane
- d. All of the above
Ans: d
21. Transdermal nicotine patch is used worldwide for –
- a. Hypertension
- b. Smoking cessation therapy
- c. Diabetes
- d. Anti-inflammatory
Ans: b
22. Stratum corneum, an outermost layer of skin is also called as
- a. Corneocytes
- b. Horny layer
- c. Hypodermis
- d. Dermis
Ans: b
23. In TDDS silicone, polyacrylate act as
- a. Adhesive
- b. Backing membrane
- c. Release liner
- d. None
Ans: a
24. Most of the drugs get absorbed through the skin by the following mechanism
- a. active transport
- b. passive transport
- c. facilitated transport
- d. osmosis
Ans: b
25. Transdermal drug delivery system is related to
- a. Dosage forms applied to intact skin
- b. Dosage form administered systemically
- c. Dosage form administered in colon
- d. None
Ans: a
26. Floating microspheres are gasto retentive drug delivery systems based on ______ approach
- a) effervescent
- b) non- effervescent
- c) Both a & b both
- d) none of these
Ans: b
27. One of the following is used as a spraying reagent in paper chromatography
- a. Conc. HCL acid
- b. NaCl solution
- c. Ninhydrin solution
- d.CuSO4 solution
Ans: c
28. Bile salts like sodium deoxycholate, sodium glycocholate are used in nasal drug delivery system as
- a. Absorption enhancers
- b. Bioadhesive
- c. Propellant
- d. Anti-allergics
Ans: a
29. Following is the rate controlling barrier evaluated for transdermal application
- a. Poly-2 hydroxyethylmethacrylate
- b. Poly-2 hydroxypropionic acid
- c. Poly-2 hydroxypropyl dimethyl ammonium chloride
- d. Both b and c
Ans: a
30. Role of chemical enhancer in transdermal drug delivery system is
- a. To increase skin permeability
- b. to decrease skin permeability
- c. Both a & b
- d. None.
Ans: a
31. Hollow microspheres are a non effervescent approach for GRDDS are also known as
- a) Microballs
- b) Microballoons
- c) Floating Beads
- d) Alginate beads
Ans: b
32. Thickness of alveolar region in Nasopulmonary Drug Delivery System is
- a) 0.1-0.5 micrometer
- b) 0.25-1.25 micrometer
- c) 1.25-2.25 micrometer
- d) 0.5-1.5 micrometer
Ans: a
33. Followings are the materials commonly used for bioadhesion except
- a) Chitosan
- b) Sodium bicarbonate
- c) Tragacanth
- d) Sodium alginate
Ans: b
34. The aerosol medication particles must be of _____ size for inhalation and deposition in the airway.
- a) 0.5-4.5μm
- b) 7. 5-12 μm
- c) Both a & b
- d) 15.5- 18.5 μm
Ans: a
35. The mechanism by which of the peptide is absorbed in nasal cavity is
- a) Tanscytoic.
- b) paracellular (intracellular)
- c) transcellular
- d) none of the above
Ans: b
36. Drugs used in ‘Nesal spray’ is/are
- a) Beclomethasone
- b) Oxymetazoline
- c) Both a & b
- d) None of these
Ans: c
37. The ideal molecular weight for the drug for Transdermal drug delivery system is_____
- a) Not more than 800 Dalton
- b) Not more than 1000 Dalton
- c) Not more than 400 Dalton
- d) Not more than 1200 Dalton
Ans: c
38. Physicochemical factor affecting TDDS is
- a) Sun light
- b) Partition coefficient
- c) Cold season
- d) Air pollution
Ans: b
39. In nasopulmonary drug delivery system the absorption can be enhanced by which of the following approaches
- a) Use of absorption enhancers
- b) Increase in residence time
- c) Use of physiological modifying agents
- d) All of the above
Ans: a
40. Normal pH of the nasal secretion in adult is
- a) 5.5-6.5
- b) 3.5-4.5
- c) 6.5-7.5
- d) 2.5-3.5
Ans: a
41. Suitable candidate for GRDDS include all, except
- a. Levodopa
- b. Ranitidine HCl
- c. Phenytoin
- d. Riboflavin
Ans: c
42. Hollow microspheres are a non effervescent approach for GRDDS are also known as
- a. Microballs
- b. Microballoons
- c. Floating Beads
- d. Alginate beads
Ans: b
43. Following drugs cannot be given as transdermal administration
- a) Drugs with very short half-lives
- b) Drugs with narrow therapeutic indices
- c) Easy removal and termination
- d) Drugs against peptic ulcer
Ans : d
44. Transdermal drug delivery system is related to
- a) Dosage forms applied to the skin
- b) Dosage forms administered systemically
- c) Dosage forms administered in colon
- d) None
Ans: a
45. From the following anatomical structure the drugs from TDDS enter the systemic circulation
- a. Epidermis
- b. Dermis
- c. Sweat glands
- d. Hypodermis
Ans: b
46. To increase the GRT, following approach is not applicable
- a. High density system
- b. Floating system
- c. Compressible system
- d. Bioadhesive system
Ans: c
47. Targeted drug delivery system is also referred as
- a. Passive targeting
- b. Active targeting
- c. Second order targeting
- d. Smart drug delivery system
Ans. d
48. The characteristic of the monolithic devices is
- a) The drug has a large therapeutic index
- b) Aqueous solutions
- c) Control drug release by partitioning the drug from the oil
- d) Administration of emulsions
Ans: a
49. Mechanism involved in nasal absorption enhancement is
- a) decreased molecular weight
- b) decreased paracellular transport
- c) increased enzymatic degradation
- d) increased Transcellular transport
Ans: d
50. Migrating mayoelectric complex (MMC) is
- a) mobility pattern of stomach
- b)gastric emptying
- c) mixing of food
- d) all of the above
Ans: a
51. Drug eluting stents are the best example of TDDSs for
- a. Vascular disease treatment
- b. Pain management
- c. Diabetes
- d. All of the above
Ans: a
52. Backing membrane, Control membrane, Matrix polymer, Adhesive layers are components of
- a. Osmotic pumps
- b. Transdermal patches
- c. Liposomes
- d. Resealed erythrocytes
Ans: b
53. In Nasopulmonary drug delivery systems the absorption can be enhanced by following approaches
- (a) Use of absorption enhancer
- (b) Increases in residence time
- (c) Use of physiological modifying agents
- (d) All of the above
Ans: d
54. Iontophoresis is used in TDDS as a
- a. Physical penetration enhancer
- b. Polymer matrix
- c. Drug Carrier
- d. Both a and b
Ans: a
55. Laurocapram & Lemon oil are used in TDDS as
- a) Adhesive
- b) Drug carrier
- c) Penetration enhancer
- d) polymer matrix
Ans: c
56. Disadvantages of drug powder inhaler is
- a) DPIs are small devices
- b) Liberation of powders from the device and segregation of particles
- c) DPIs are portable devices
- d) None of the above
Ans: b